Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gicitinib plus standard immunotherapy for first-line treatment of chronic graft-versus-host disease
ChiCTR2600125048Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gicitinib in chronic graft-versus-host disease (cGVHD), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Overall response rate at 24 weeks (primary). Started May 2026; status: recruiting.
02
Drugs
gicitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ChiCTR2600125048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125048.